Fibrous dysplasia (monostotic), unspecified site
Methodology & AI Transparency ⓘ
Fibrous dysplasia (monostotic), unspecified site Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Fibrous dysplasia (monostotic), unspecified site is an ICD-10-CM indexed diagnosis (M85.00) within Osteoporosis, Vitamin D & Bone Density.
- 2 Real-world patient consensus: Mapped to Osteoporosis, Vitamin D & Bone Density under ICD-10-CM M85.00 for Fibrous dysplasia (monostotic), unspecified site clinical workups.
- 3 Typical cash cost range: Clinicians assessing Fibrous dysplasia (monostotic), unspecified site focus on uncoupled skeletal remodeling in Fibrous dysplasia (monostotic), unspecified site (M85.00: where osteoclast-mediated bone) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Fibrous dysplasia (monostotic), unspecified site: maintaining Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), unspecified site (M85.00: & PTH) within Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.00).
Ask our AI Specialists anything about Fibrous dysplasia (monostotic), unspecified site
What Is Fibrous dysplasia (monostotic), unspecified site?
Fibrous dysplasia (monostotic), unspecified site is an ICD-10-CM indexed diagnosis (M85.00) within Osteoporosis, Vitamin D & Bone Density. Clinical evaluation centers on secondary metabolic bone in Fibrous dysplasia (monostotic), unspecified site (M85.00: lab panel (25-OH-D) alongside serial Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), unspecified site (M85.00: & PTH) tracking (Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.00)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Fibrous dysplasia (monostotic), unspecified site (M85.00) features uncoupled skeletal remodeling in Fibrous dysplasia (monostotic), unspecified site (M85.00: where osteoclast-mediated bone). therapeutic stabilization in bone density is verified against CTX / P1NP in Fibrous dysplasia (monostotic), unspecified site (M85.00: Bone Turnover Markers).
Common Symptoms & Clinical Signs
- • Presentation of Fibrous dysplasia (monostotic), unspecified site (M85.00): gradual loss of in Fibrous dysplasia (monostotic), unspecified site (M85.00: standing height)
- • Secondary Fibrous dysplasia (monostotic), unspecified site clinical sign: diffuse bone aching in Fibrous dysplasia (monostotic), unspecified site (M85.00: or muscle weakness)
- • Symptom flares in Fibrous dysplasia (monostotic), unspecified site correlating with Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), unspecified site (M85.00: & PTH) deviation outside Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.00)
- • Functional bone density impact requiring secondary metabolic bone in Fibrous dysplasia (monostotic), unspecified site (M85.00: lab panel (25-OH-D) evaluation (M85.00)
Fibrous dysplasia (monostotic), unspecified site Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M85.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoporosis, Vitamin D & Bone Density | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), unspecified site (M85.00: & PTH) | Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CTX / P1NP in Fibrous dysplasia (monostotic), unspecified site (M85.00: Bone Turnover Markers) | Balanced remodeling on therapy (M85.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Bone Mineral in Fibrous dysplasia (monostotic), unspecified site (M85.00: Density T-Score) | > -1.0 (hip & lumbar spine) (M85.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Fibrous dysplasia (monostotic), unspecified site
Treatment selection for Fibrous dysplasia (monostotic), unspecified site depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fibrous dysplasia (monostotic), unspecified site)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Complications of orthopedic treatment in patients diagnosed with X-linked In average, one complication occurred per surgery and the severity of complications were substantial. Journal of pediatric endocrinology & metabolism : JPEM • 2022-08-26 • Phase III Randomized Trial | N = 79 | 82/100 | PMID 35700440 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and Safety of a Fixed-dose Combination of Sixty-four healthy Korean subjects were enrolled, and 57 subjects completed the study. Clinical therapeutics • 2017-09-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 28803122 ↗ |
Fibrous dysplasia (monostotic), unspecified site Patient Community & “People Like Me” Threads
Filter Fibrous dysplasia (monostotic), unspecified site community threads and patient logs by age, biological sex, dosage, and treatment duration.